A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(18 sites)

Russia

Territorial State Budgetary Institution, Barnaul

Federal State Budgetary Institution of Science, Kirov

Federal State Budgetary Institution, Moscow

Hematology Centre based on City Clin. Hosp. n.a. S.P. Botkin, Moscow

Federal State Budgetary Institution, Saint Petersburg